Literature DB >> 23979493

Mefloquine, a new type of compound against schistosomes and other helminthes in experimental studies.

Shu-hua Xiao1.   

Abstract

Up to date, schistosomiasis is still prevalent worldwide. It is estimated that more than 200 million individuals are infected, and 120 million suffer from clinical morbidity. Facing such huge cases of schistosomiasis, only heavy reliance on a single praziquantel for schistosomiasis control does not adapt and may promote the selection and spread of drug-resistant parasites. Therefore, it is an urgent need to develop the new antischistosomal drug. In 2008-2009, the antimalarial drug mefloquine, an arylaminoalcohol compound, has been found to be effective against schistosomes. According to the experimental studies, the deepest impression on the antischistosomal properties of mefloquine can be summarized as following points: (1) single dose of mefloquine possesses potential effect against three major species of schistosomes (Schistosoma mansoni, Schistosoma haematobium, and Schistosoma japonicum) infecting humans; (2) the drug displays similar effects against developing stages of juvenile and adult schistosomes, which are superior to that of artemisinins and praziquantel; (3) in vitro mefloquine exerts direct killing effect on juvenile and adult schistosomes, while in vivo, the efficacy of the drug is independent to host immune response, (4) mefloquine causes extensive and severe morphological, histopathological, and ultrastructural damage to adult and juvenile schistosomes, particularly, the worm tegument, musculature, gut, and vitelline glands of female worms are the key sites attacked by the drug; (5) combined treatment with mefloquine and praziquantel, or artemisinins shows synergistic effect against schistosome in experimental therapy,while in initially clinical trial, mefloquine in combination with artesunate also exhibits higher cure rates against schistosomiasis hematobia and schistosomiasis mansoni, and (6) several mefloquine-related arylmethanols exhibit potential effect against schistosomes in vivo, which is a useful clue helpful for development of new antischistosomal compound. In the present review, we have summarized the major results published in recent years, and the significance as well as the prospect for the future study of mefloquine have been discussed briefly.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23979493     DOI: 10.1007/s00436-013-3559-0

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  71 in total

Review 1.  Antimalarials in the treatment of schistosomiasis.

Authors:  Jennifer Keiser; Jurg Utzinger
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 2.  [Progress in development of new antischistosomal drugs in recent years].

Authors:  Shu-Hua Xiao
Journal:  Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi       Date:  2010-06-30

Review 3.  Development of antischistosomal drugs in China, with particular consideration to praziquantel and the artemisinins.

Authors:  Shu-Hua Xiao
Journal:  Acta Trop       Date:  2005-08-19       Impact factor: 3.112

4.  Susceptibility of Schistosoma japonicum to different developmental stages to praziquantel.

Authors:  S H Xiao; W J Yue; Y Q Yang; J Q You
Journal:  Chin Med J (Engl)       Date:  1987-09       Impact factor: 2.628

5.  Disposition of mefloquine and enpiroline is highly influenced by a chronic Schistosoma mansoni infection.

Authors:  Katrin Ingram; Urs Duthaler; Mireille Vargas; William Ellis; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2013-07-08       Impact factor: 5.191

6.  Effect of combined treatment with praziquantel and artemether on Schistosoma japonicum and Schistosoma mansoni in experimentally infected animals.

Authors:  J Utzinger; J Chollet; J You; J Mei; M Tanner; S Xiao
Journal:  Acta Trop       Date:  2001-09-01       Impact factor: 3.112

7.  Tegumental alterations of adult Schistosoma japonicum harbored in mice treated with a single oral dose of mefloquine.

Authors:  Shu-hua Xiao; Jian Xue; Bing-gui Shen
Journal:  Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi       Date:  2010-02

8.  Identification of an antimalarial synthetic trioxolane drug development candidate.

Authors:  Jonathan L Vennerstrom; Sarah Arbe-Barnes; Reto Brun; Susan A Charman; Francis C K Chiu; Jacques Chollet; Yuxiang Dong; Arnulf Dorn; Daniel Hunziker; Hugues Matile; Kylie McIntosh; Maniyan Padmanilayam; Josefina Santo Tomas; Christian Scheurer; Bernard Scorneaux; Yuanqing Tang; Heinrich Urwyler; Sergio Wittlin; William N Charman
Journal:  Nature       Date:  2004-08-19       Impact factor: 49.962

9.  Activity of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine against Schistosomiasis mansoni in mice.

Authors:  Sanaa Botros; Samia William; Olfat Hammam; Zdenĕk Zídek; Antonín Holý
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

10.  Further study on mefloquine concerning several aspects in experimental treatment of mice and hamsters infected with Schistosoma japonicum.

Authors:  Shu-hua Xiao; Jing-yan Mei; Pei-ying Jiao
Journal:  Parasitol Res       Date:  2009-10-02       Impact factor: 2.289

View more
  13 in total

1.  Radicicol, a Novel Lead Compound against the Migratory-Stage Schistosomula of Schistosoma japonicum.

Authors:  Liangxiong Xu; Qiuli Liu; Qingren Zeng; Ping Wu; Quan Yu; Kongzhen Gu; Jinghua Xue; Xiaoyi Wei
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

2.  Derivatives of biarylalkyl carboxylic acid induce pleiotropic phenotypes in adult Schistosoma mansoni in vitro.

Authors:  Ariane S Blohm; Patrick Mäder; Thomas Quack; Zhigang Lu; Steffen Hahnel; Martin Schlitzer; Christoph G Grevelding
Journal:  Parasitol Res       Date:  2016-05-26       Impact factor: 2.289

3.  In vivo and in vitro efficacies of mebendazole, mefloquine and nitazoxanide against cyst echinococcosis.

Authors:  Congshan Liu; Haobing Zhang; Jianhai Yin; Wei Hu
Journal:  Parasitol Res       Date:  2015-03-15       Impact factor: 2.289

4.  Efficacy and safety of arachidonic acid for treatment of Schistosoma mansoni-infected children in Menoufiya, Egypt.

Authors:  Sahar Selim; Ola El Sagheer; Azza El Amir; Rashida Barakat; Kevin Hadley; Maaike J Bruins; Rashika El Ridi
Journal:  Am J Trop Med Hyg       Date:  2014-09-22       Impact factor: 2.345

5.  Effect of ozonide OZ418 against Schistosoma japonicum harbored in mice.

Authors:  Jian Xue; Xiaofang Wang; Yuxiang Dong; Jonathan L Vennerstrom; Shu-hua Xiao
Journal:  Parasitol Res       Date:  2014-06-20       Impact factor: 2.289

6.  Significance of higher drug concentration in erythrocytes of mice infected with Schistosoma japonicum and treated orally with mefloquine at single doses.

Authors:  Yi Tao; Jian Xue; Bin Jiang; Hao-Bing Zhang; Shu-Hua Xiao
Journal:  Parasitol Res       Date:  2015-09-04       Impact factor: 2.289

7.  Mitochondria as a Potential Target for the Development of Prophylactic and Therapeutic Drugs against Schistosoma mansoni Infection.

Authors:  Keith Kiplangat Talaam; Daniel Ken Inaoka; Takeshi Hatta; Daigo Tsubokawa; Naotoshi Tsuji; Minoru Wada; Hiroyuki Saimoto; Kiyoshi Kita; Shinjiro Hamano
Journal:  Antimicrob Agents Chemother       Date:  2021-08-02       Impact factor: 5.191

8.  Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children (SchistoSAM): protocol of a proof-of-concept, open-label, two-arm, individually-randomised controlled trial.

Authors:  Clémentine Roucher; Isabel Brosius; Katja Polman; Emmanuel Bottieau; Moustapha Mbow; Babacar Thiendella Faye; Annelies De Hondt; Bart Smekens; Diana Arango; Christophe Burm; Achilleas Tsoumanis; Linda Paredis; Yven van Herrewege; Idzi Potters; Badara Cisse; Souleymane Mboup
Journal:  BMJ Open       Date:  2021-06-24       Impact factor: 2.692

9.  Discovery by organism based high-throughput screening of new multi-stage compounds affecting Schistosoma mansoni viability, egg formation and production.

Authors:  Alessandra Guidi; Cristiana Lalli; Roberto Gimmelli; Emanuela Nizi; Matteo Andreini; Nadia Gennari; Fulvio Saccoccia; Steven Harper; Alberto Bresciani; Giovina Ruberti
Journal:  PLoS Negl Trop Dis       Date:  2017-10-06

Review 10.  Application of Dendrimers for the Treatment of Infectious Diseases.

Authors:  Zandile Mhlwatika; Blessing Atim Aderibigbe
Journal:  Molecules       Date:  2018-08-31       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.